Unknown

Dataset Information

0

HTLV-1 CTCF-binding site is dispensable for in vitro immortalization and persistent infection in vivo.


ABSTRACT: BACKGROUND:Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukemia/lymphoma (ATL) and the neurological disorder HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The exact mechanism(s) through which latency and disease progression are regulated are not fully understood. CCCTC-binding factor (CTCF) is an 11-zinc finger, sequence-specific, DNA-binding protein with thousands of binding sites throughout mammalian genomes. CTCF has been shown to play a role in organization of higher-order chromatin structure, gene expression, genomic imprinting, and serve as a barrier to epigenetic modification. A viral CTCF-binding site (vCTCF-BS) was previously identified within the overlapping p12 (sense) and Hbz (antisense) genes of the HTLV-1 genome. Thus, upon integration, HTLV-1 randomly inserts a vCTCF-BS into the host genome. vCTCF-BS studies to date have focused primarily on HTLV-1 chronically infected or tumor-derived cell lines. In these studies, HTLV-1 was shown to alter the structure and transcription of the surrounding host chromatin through the newly inserted vCTCF-BS. However, the effects of CTCF binding in the early stages of HTLV-1 infection remains unexplored. This study examines the effects of the vCTCF-BS on HTLV-1-induced in vitro immortalization and in vivo viral persistence in infected rabbits. RESULTS:HTLV-1 and HTLV-1?CTCF LTR-transactivation, viral particle production, and immortalization capacity were comparable in vitro. The total lymphocyte count, proviral load, and Hbz gene expression were not significantly different between HTLV-1 and HTLV-1?CTCF-infected rabbits throughout a 12 week study. However, HTLV-1?CTCF-infected rabbits displayed a significantly decreased HTLV-1-specific antibody response compared to HTLV-1-infected rabbits. CONCLUSIONS:Mutation of the HTLV-1 vCTCF-BS does not significantly alter T-lymphocyte transformation capacity or early in vivo virus persistence, but results in a decreased HTLV-1-specific antibody response during early infection in rabbits. Ultimately, understanding epigenetic regulation of HTLV-1 gene expression and pathogenesis could provide meaningful insights into mechanisms of immune evasion and novel therapeutic targets.

SUBMITTER: Martinez MP 

PROVIDER: S-EPMC6925871 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

HTLV-1 CTCF-binding site is dispensable for in vitro immortalization and persistent infection in vivo.

Martinez Michael P MP   Cheng Xiaogang X   Joseph Ancy A   Al-Saleem Jacob J   Panfil Amanda R AR   Palettas Marilly M   Dirksen Wessel P WP   Ratner Lee L   Green Patrick L PL  

Retrovirology 20191221 1


<h4>Background</h4>Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukemia/lymphoma (ATL) and the neurological disorder HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The exact mechanism(s) through which latency and disease progression are regulated are not fully understood. CCCTC-binding factor (CTCF) is an 11-zinc finger, sequence-specific, DNA-binding protein with thousands of binding sites throughout mammalian genomes. CTCF has been s  ...[more]

Similar Datasets

| S-EPMC4801255 | biostudies-literature
| S-EPMC2974607 | biostudies-literature
| S-EPMC3091324 | biostudies-literature
| S-EPMC8500713 | biostudies-literature
| S-EPMC2944806 | biostudies-other
| S-EPMC4295388 | biostudies-literature
| S-EPMC6305241 | biostudies-literature